AGAlessandro Lo Giudice

Alessandro Lo Giudice

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alessandro Lo Giudice has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Understanding and Mimicking Glioblastoma Cells Migration Strategies Through Hydrogel-Based 3D Models

    by Alessandro Lo Giudice, Martina Di Marco, Giulia Maria Giorgia Lo Piano, Francesca Chiara Cecala, Claudia Campanella, Francesco Cappello, Celeste Caruso Bavisotto, Giuseppa D’Amico, Alessandra Maria Vitale

    Glioblastoma (GBM) is one of the most aggressive primary brain tumors in adults, characterized by rapid growth, diffuse infiltration of surrounding brain parenchyma, and resistance to conventional therapies, resulting in poor prognosis. The diffuse infiltrative behavior of GBM represents a major therapeutic challenge, as cancer cells can disseminate beyond identifiable margins of the tumor, escaping complete eradication and contributing to recurrence. GBM cell migration is a heterogeneous process that can occur through distinct strategies, including single-cell and collective patterns, as well as through the formation of multicellular structures known as “oncostreams”. Understanding the mechanisms underlying these migratory modalities may help identify new targets for limiting local tumor dissemination and disease progression. In this context, a variety of in vitro models have been developed to investigate these processes. Among these, hydrogel-based scaffolds represent a promising platform to recapitulate some selected biochemical and biophysical properties of the brain extracellular matrix, enabling the investigation of how the extracellular environment cues influence GBM cell migration and invasion. In this review, we discuss the major cellular strategies of GBM cell migration and tissue invasion and critically examine hydrogel-based in vitro models used to investigate these processes, highlighting their design principles, biological relevance, and current limitations.

  • Open Access

    Standardized Workflow for the Generation of Patient-Derived Glioblastoma Spheroids

    by Giuseppa D’Amico, Alessandra Maria Vitale, Martina Di Marco, Alessandro Lo Giudice, Francesca Chiara Cecala, Francesco Cappello, Celeste Caruso Bavisotto

    Glioblastoma (GBM) is one of the most aggressive and therapy-resistant primary brain tumors, mainly due to its pronounced intratumoral heterogeneity and highly invasive phenotype. Patient-derived three-dimensional (3D) culture models, including tumor spheroids, represent valuable tools to preserve the cellular complexity, phenotypic plasticity, and microenvironmental features of GBM ex vivo. However, standardized and reproducible protocols for the generation and maintenance of GBM spheroids from surgical specimens are still limited. Here, we describe a detailed and robust protocol for the isolation, 3D cultures, and expansion of primary GBM cells obtained from patient biopsies, leading to the formation of stable and morphologically consistent spheroids. The protocol provides step-by-step instructions for tissue dissociation, cell seeding under low-adhesion conditions, optimization of culture density, and long-term spheroid maintenance. In addition, we include guidelines for the morpho-phenotypical characterization of the resulting 3D structures. This methodological workflow offers a reproducible platform for modeling GBM in vitro, enabling the study of tumor biology and supporting translational applications such as drug screening, biomarker validation, and patient-specific therapeutic testing in a 3D context.


  • Open Access

    GSCs in the Transdifferentiation Phenomenon: Focus on CAR-T-Based Therapy

    by Martina Di Marco, Alessandro Lo Giudice, Francesca Chiara Cecala, Sabrina David, Celeste Caruso Bavisotto, Claudia Campanella, Alessandra Maria Vitale, Giuseppa D’amico

    Glioblastoma (GBM) remains one of the most lethal brain tumors, largely due to the resilience and plasticity of glioblastoma stem cells (GSCs), which drive tumor growth, recurrence, and resistance to conventional therapies. A key mechanism underlying their aggressiveness is transdifferentiation, whereby GSCs acquire endothelial- and pericyte-like phenotypes, promoting neovascularization and remodeling the tumor microenvironment to sustain malignancy. Conventional treatments often fail to eliminate these resilient populations, highlighting the need for innovative targeted strategies. Chimeric antigen receptor (CAR)-based immunotherapies offer a targeted strategy to specifically eliminate GSCs and interfere with their role in promoting tumor vascularization and suppressing immune responses. This review aims to provide a comprehensive overview of the molecular mechanisms driving GSC transdifferentiation and to summarize the current landscape of CAR-T therapies developed to target these cells. By integrating knowledge of GSC biology with advances in CAR-T-based interventions, this work highlights the potential of next-generation immunotherapies to overcome therapeutic resistance, limit tumor recurrence, and improve clinical outcomes in GBM.